Three-year results from a multicenter phase II study of capecitabine plus paclitaxel in metastatic breast cancer.

被引：0
|
作者：
Gradishar, WJ
Meza, L
Hill, T
Chen, YM
Varkey, JA
Hei, Y
Amin, B
机构：
[1] Northwestern Univ, Sch Med, Chicago, IL 60611 USA
[2] SW Oncol Associates, Lafayette, LA USA
[3] Roche Labs, Nutley, NJ USA
[4] Mid Dakota Clin, Bismarck, MD USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2002年 / 76卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
335
引用
收藏
页码：S90 / S90
页数：1
相关论文
共 50 条
  • [1] Capecitabine plus paclitaxel as first-or second-line therapy: a multicenter phase II study in metastatic breast cancer.
    Meza, LA
    Amin, B
    Hill, T
    Chen, YM
    Petralia, SA
    Gradishar, WJ
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 271 - 271
  • [2] Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
    Blum, JL
    Jones, SE
    Buzdar, AU
    LoRusso, PM
    Kuter, I
    Vogel, C
    Osterwalder, B
    Burger, HU
    Brown, CS
    Griffin, T
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) : 485 - 493
  • [3] Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: A multicenter phase II study
    Gradishar, WJ
    Meza, LA
    Amin, B
    Samid, D
    Hill, T
    Chen, YM
    Lower, EE
    Marcom, PK
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) : 2321 - 2327
  • [4] Low dose capecitabine plus weekly paclitaxel in patients with metastatic breast cancer: a multicenter phase II study KBCSG-0609
    Taguchi, Tetsuya
    Yamamoto, Daigo
    Masuda, Norikazu
    Oba, Koji
    Nakayama, Takahiro
    Nagata, Takuya
    Nomura, Masaya
    Yoshidome, Katsuhide
    Yoshino, Hiroshi
    Matsunami, Nobuki
    Miyashita, Masaru
    Furuya, Yoshihiko
    Ishida, Takanori
    Wakita, Kazuyuki
    Sakamoto, Junichi
    Noguchi, Shinzaburo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (03) : 741 - 747
  • [5] Low dose capecitabine plus weekly paclitaxel in patients with metastatic breast cancer: a multicenter phase II study KBCSG-0609
    Tetsuya Taguchi
    Daigo Yamamoto
    Norikazu Masuda
    Koji Oba
    Takahiro Nakayama
    Takuya Nagata
    Masaya Nomura
    Katsuhide Yoshidome
    Hiroshi Yoshino
    Nobuki Matsunami
    Masaru Miyashita
    Yoshihiko Furuya
    Takanori Ishida
    Kazuyuki Wakita
    Junichi Sakamoto
    Shinzaburo Noguchi
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 741 - 747
  • [6] Mitomycin c plus capecitabine (MiXe) in anthracycline- and taxane-pretreated metastatic breast cancer. A multicenter phase II study
    Maisano, Roberto
    Caristi, Nicola
    Mare, Marzia
    Raffaele, Mario
    Iorfida, Monica
    Mafodda, Antonino
    Zavettieri, Maria
    Nardi, Mario
    ANTICANCER RESEARCH, 2007, 27 (4C) : 2871 - 2875
  • [7] Phase II and pharmacological study of oral paclitaxel plus cyclosporine A in anthracycline pretreated metastatic breast cancer.
    Helgason, HH
    Kruijtzer, CMF
    Huitema, ADR
    Marcus, S
    Ten Bokkel-Huinink, WW
    Schot, ME
    Schornagel, JH
    Beijnen, JH
    Schellens, JHM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 41S - 41S
  • [8] Phase II study of carboplatin, vinorelbine and capecitabine in patients with metastatic breast cancer.
    Rabinowitz, MJ
    Mangalik, A
    Lee, FC
    Cynthia, C
    Claire, V
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S203 - S203
  • [9] Phase I/II study of carboplatin, vinorelbine and capecitabine in metastatic breast cancer.
    Rabinowitz, MJ
    Mangalik, A
    Lee, FC
    Cathcart, C
    Verschraegen, C
    Rabinowitz, I
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 57S - 57S
  • [10] Phase II study of bavituximab plus paclitaxel and carboplatin in locally advanced or metastatic breast cancer: Interim results
    Jain, M.
    Raizada, N.
    Kuttan, R.
    Shan, J.
    Digumarti, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345